Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial
- Pfisterer, Jacobus
- Shannon, Catherine
- Baumann, Klaus
- Rau, Joern
- Harter, Philipp
- Joly, Florence
- Sehouli, Jalid
- Canzler, Ulrich
- Schmalfeldt, Barbara
- Dean, Andrew
- Hein, Alexander
- Zeimet, Alain
- Hanker, Lars
- Petit, Thierry
- Marme, Frederik
- El-Balat, Ahmed
- Glasspool, Rosalind
- de Gregorio, Nikolaus
- Mahner, Sven
- Meniawy, Tarek
- Park-Simon, Tjoung-Won
- Mouret-Reynier, Marie-Ange
- Costan, Cristina
- Meier, Werner
- Reinthaller, Alexander
- Goh, Jeffrey
- L'Haridon, Tifenn
- Baron Hay, Sally
- Kommoss, Stefan
- Du Bois, Andreas
- Kurtz, Jean-Emmanuel
- Ackermann, Sven
- Anthuber, Christoph
- Aydogdu, Mustafa
- Baldauf, Angelika
- Bauer, Wolfgang
- Behringer, Dirk
- Belau, Antje
- Bender, Alexandra
- Brucker, Cosima
- Burges, Alexander
- Daabach, Trygve
- Denschlag, Dominik
- Deryal, Mustafa
- Dörfel, Steffen
- Ebert, Juliane
- Fehm, Tanja
- Feidicker, Susanne Maria
- Feisel-Schwickardi, Gabriele
- Felberbaum, Ricardo
- Frank, Matthias
- Gebauer, Gerhard
- Gerber, Bernd
- Gerhardt, Axel
- Grafe, Andrea
- Griesshammer, Martin
- Grischke, Eva-Maria
- Gröll, Isolde
- Gropp-Meier, Martina
- Hager, Dietrich
- Hanf, Volker
- Hannig, Carla Verena
- Hantschmann, Peer
- Hauzenberger, Tanja
- Herwig, Uwe
- Heubner, Martin
- Hielscher, Carsten
- Hilpert, Felix
- Hitschold, Thomas
- Hofmann, Manfred
- Jackisch, Christian
- Janni, Wolfgang
- Kiesel, Ludwig
- Ko, Yon-Dschun
- Koch, Hans-Joachim
- Krabisch, Petra
- Krieger, Peter
- Kubin, Thomas
- Kühn, Thorsten
- Lampe, Björn
- Ledwon, Peter
- Lemster, Sabine
- Lex, Benno
- Liebrich, Clemens
- Lorenz, Ralf
- Lück, Hans-Joachim
- Mallmann, Peter
- Meinerz, Wolfgang
- Menke, Götz
- Möbus, Volker
- Muller, Thomas
- Müller, Volker
- Neunhöffer, Tanja
- Ober, Angelika
- Oskay-Özcelik, Gülten
- Ostertag, Horst
- Pölcher, Martin
- Rautenberg, Beate
- Rein, Daniel
- Reiter, Wilhelm
- Rempen, Andreas
- Runnebaum, Ingo
- Schmidt, Marcus
- Schnohr, Sabine
- Scholz, Heinz
- Schröder, Willibald
- Simon, Eike
- Sperfeld, Antje
- Steckkönig, Annette
- Strauss, Hans-Georg
- Stuth, Ronaldo
- Terhaag, Jürgen
- Thiel, Falk
- Thill, Marc
- Tomé, Oliver
- Uleer, Christoph
- Vogel, Susanne
- Voss, Hermann
- Weigel, Michael
- Winkler, Ulrich
- Wischnik, Arthur
- Zeiser, Tobias
- Zorr, Andreas
- Glasspool, Ros
- Hudson, Emma
- Jones, Rachel
- Lafleur, Judith
- Marth, Christian
- Petru, Edgar
- Antill, Yoland
- Azer, Mary
- Baron-Hay, Sally
- Beale, Philip
- Begbie, Stephen
- Black, Allison
- Briscoe, Karen
- Harvey, Sandra
- Lee, Chee
- Matos, Marco
- Olesen, Inger
- Vasey, Paul
- Abadie-Lacourtoisie, Sophie
- Arsene, Olivier
- Barthier, Sophie
- Becuwe-Roemer, Célia
- Berton-Rigaud, Dominique
- Cappiello-Bataller, Maria
- Catala, Stéphanie
- del Piano, Francesco
- Deplanque, Gaël
- Despax, Raymond
- Dohollou, Nadine
- Garnier-Tixidré, Claire
- Grenier, Julien
- Guardiola, Emmanuel
- Hardy-Bessard, Anne-Claire
- Lefeuvre-Plesse, Claudia
- Leheurteur, Marianne
- Lesoin, Anne
- Levache, Charles-Briac
- Longo, Raffaele
- Lortholary, Alain
- Meunier, Jérôme
- Raban, Nadia
- Romano, Olivier
- Vannetzel, Jean-Michel
- Zannetti, Alain
DOIAbstract
International audienceState-of-the art therapy for recurrent ovarian cancer suitable for platinum-based re-treatment includes bevacizumab-containing combinations (eg, bevacizumab combined with carboplatin-paclitaxel or carboplatin-gemcitabine) or the most active non-bevacizumab regimen: carboplatin-pegylated liposomal doxorubicin. The aim of this head-to-head trial was to compare a standard bevacizumab-containing regimen versus carboplatin-pegylated liposomal doxorubicin combined with bevacizumab
Add to ORKG